Structure-activity Relationship of Pyrazol-4-yl-pyridine Derivatives and Identification of a Radiofluorinated Probe for Imaging the Muscarinic Acetylcholine Receptor M
Overview
Authors
Affiliations
There is an accumulating body of evidence implicating the muscarinic acetylcholine receptor 4 (M) in schizophrenia and dementia with Lewy bodies, however, a clinically validated M positron emission tomography (PET) radioligand is currently lacking. As such, the aim of this study was to develop a suitable M PET ligand that allows the non-invasive visualization of M in the brain. Structure-activity relationship studies of pyrazol-4-yl-pyridine derivates led to the discovery of target compound a subtype-selective positive allosteric modulator (PAM). The radiofluorinated analogue, [F], was synthesized in 28 ± 10% radiochemical yield, >37 GBq/μmol and an excellent radiochemical purity >99%. Initial autoradiograms on rodent brain sections were performed in the absence of carbachol and showed moderate specificity as well as a low selectivity of [F] for the M-rich striatum. However, in the presence of carbachol, a significant increase in tracer binding was observed in the rat striatum, which was reduced by >60% under blocking conditions, thus indicating that orthosteric ligand interaction is required for efficient binding of [F] to the allosteric site. Remarkably, however, the presence of carbachol was not required for high specific binding in the non-human primate (NHP) and human striatum, and did not further improve the specificity and selectivity of [F] in higher species. These results pointed towards significant species-differences and paved the way for a preliminary PET study in NHP, where peak brain uptake of [F] was found in the putamen and temporal cortex. In conclusion, we report on the identification and preclinical development of the first radiofluorinated M PET radioligand with promising attributes. The availability of a clinically validated M PET radioligand harbors potential to facilitate drug development and provide a useful diagnostic tool for non-invasive imaging.
Qi A, Kling H, Billard N, Rodriguez A, Peng L, Dickerson J Mol Pharmacol. 2023; 104(5):195-202.
PMID: 37595966 PMC: 10586508. DOI: 10.1124/molpharm.122.000643.
Imaging Cholinergic Receptors in the Brain by Positron Emission Tomography.
Zhang J, Fu H, Lin R, Zhou J, Haider A, Fang W J Med Chem. 2023; 66(16):10889-10916.
PMID: 37583063 PMC: 10461233. DOI: 10.1021/acs.jmedchem.3c00573.
Jorg M, van der Westhuizen E, Lu Y, Choy K, Shackleford D, Khajehali E Eur J Med Chem. 2023; 258:115588.
PMID: 37423123 PMC: 7616163. DOI: 10.1016/j.ejmech.2023.115588.
Recessive CHRM5 variant as a potential cause of neurogenic bladder.
Schneider S, Schierbaum L, Burger W, Seltzsam S, Wang C, Zheng B Am J Med Genet A. 2023; 191(8):2083-2091.
PMID: 37213061 PMC: 10527291. DOI: 10.1002/ajmg.a.63241.